Halozyme Therapeutics (HALO) Tops Q3 EPS by 11c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.62 -0.26%
Revenue Growth %: +37.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
WMK, FACO, SEB, More
Revenue Growth %: +37.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
WMK, FACO, SEB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.72, $0.11 better than the analyst estimate of $1.61. Revenue for the quarter came in at $354 million versus the consensus estimate of $340.12 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $6.10-$6.50, versus the consensus of $5.18. Halozyme Therapeutics sees FY2025 revenue of $1.3-1.375 billion, versus the consensus of $1 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Nordisk (NVO) Tops Q3 EPS by 117c; offers outlook
- Ashland (ASH) Misses Q4 EPS by 16c ; Offers Guidance
- Morgan Stanley Upgrades Yamaha Corporation (7951:JP) (YAMCY) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
